LOGIN  |  REGISTER
Astria Therapeutics
C4 Therapeutics

Ensign Acquires Real Estate in Texas

February 03, 2025 | Last Trade: US$167.99 0.96 -0.57

SAN JUAN CAPISTRANO, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced today that its captive real estate company, Standard Bearer Healthcare REIT, Inc. exercised a purchase option to acquire the real estate of the following skilled nursing facilities and healthcare campus effective as of January 31, 2025:

  • Beacon Harbor Healthcare & Rehabilitation, a 190-bed skilled nursing facility located in Rockwall, Texas;
  • Pleasant Manor Healthcare & Rehabilitation, a 126-bed skilled nursing facility located in Waxahachie, Texas;
  • Rowlett Health & Rehabilitation Center, a 150-bed skilled nursing facility located in Rowlett, Texas; and
  • Crestwood Health & Rehabilitation Center, a healthcare campus with 112 skilled nursing beds and 36 assisted living units located in Wills Point, Texas.

Each of these operations have been operated by an Ensign-affiliated company under two third-party leases with purchase options since 2019. These facilities will continue to be operated by independent operating subsidiaries of Ensign and subject to long-term triple net leases with Standard Bearer. “We have been anxiously waiting to exercise the purchase options on these leased operations,” said Chad Keetch, Ensign's Chief Investment Officer. “These operations are already strong performers both culturally and financially, and we still see tremendous upside in each of them. As these operations continue to mature, we expect to create even more value in both the operations and the real estate,” he added.

“This acquisition showcases one of the many avenues available to Standard Bearer for growth. Where possible, we will continue to use our reputation as a top-notch operator to obtain purchase options in our leases, which allows us to grow our operations while also letting us capture the upside created in the real estate,” Keetch said.

In a separate transaction effective February 1, 2025, Ensign announced that it had acquired the real estate and operations to Mesquite Post Acute Care, a 120-bed skilled nursing facility located in Lubbock, Texas. The real estate was acquired by a subsidiary of Standard Bearer and will be operated by an independent operating subsidiary of Ensign subject to a long-term triple net lease with Standard Bearer.

These acquisitions bring Ensign's growing portfolio to 334 healthcare operations, 30 of which also include senior living operations, across 15 states.  Ensign subsidiaries, including Standard Bearer, own 134 real estate assets. Mr. Keetch reaffirmed that Ensign is actively seeking opportunities to acquire real estate and to lease both well-performing and struggling skilled nursing, senior living and other healthcare related businesses throughout the United States.

About Ensign™

The Ensign Group, Inc.'s independent operating subsidiaries provide a broad spectrum of skilled nursing and senior living services, physical, occupational and speech therapies and other rehabilitative and healthcare services at 334 healthcare facilities in Alabama, Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Tennessee, Texas, Utah, Washington and Wisconsin. More information about Ensign is available at http://www.ensigngroup.net.

Contact Information

The Ensign Group, Inc., (949) 487-9500, This email address is being protected from spambots. You need JavaScript enabled to view it. 

Assertio

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page